[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Russian Cardiology Research and Production Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100632072","russian-extreme-hypertriglyceridemia-registry-100632072",false,"NCT07508930","Russian Extreme Hypertriglyceridemia Registry","Russian Extreme Hypertriglyceridemia Registry (REGGI)","REGGI","Inclusion Criteria:\n\n* Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol\u002FL), confirmed by at least two independent measurements.\n* Written informed consent from the patient or legal guardian.\n* No age restrictions.\n\nExclusion Criteria:\n\n* Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition.\n* Lack of informed consent.","ALL",{"count":19,"type":20},500,"ESTIMATED","20 Years","OBSERVATIONAL","The REGGI registry is a prospective, multicenter observational registry in Russia designed to collect data on patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol\u002FL). The registry aims to describe the clinical, demographic, and molecular-genetic characteristics of patients, as well as current diagnostic approaches and treatment patterns in real-world practice. The collected data may inform future research and support improvements in patient care.",[25],"Hypertriglyceridemia",[27,28],"Acute Pancreatitis","cardiovascular diseases","RECRUITING","2026-03-27",{"date":32,"type":33},"2026-04-02","ACTUAL",{"date":35,"type":33},"2025-11-20",{"date":37,"type":20},"2045-12",{"name":39,"class":40},"Russian Cardiology Research and Production Center","OTHER",6,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100225171","russian-familial-hypercholesterolemia-registry-100225171","NCT02208869","Russian Familial Hypercholesterolemia Registry","Prospective Russian Study Evaluating the Extent of Underdiagnosed and Undertreated of Familial Hypercholesterolaemia in the Population","RuFH","Inclusion Criteria:\n\n* Total cholesterol ≥7.5 mmol\u002FL or LDL-C ≥4.9 mmol\u002FL (pretreatment levels)\n* Familial hypercholesterolemia defined as: a. Mutation in the LDL receptor and\u002For the ApoB gene and\u002For the PCSK9 gene; or b. clinical diagnosis of heterozygous FH (HeFH) according to the Dutch Lipid Network Criteria or Simon Broom Criteria\n* Patients with genetic mutation of FH\n\nExclusion Criteria:\n\n* uncontrolled primary hypothyroidism (thyroid stimulating hormone (TSH) \\>1.5 x upper limit of normal (ULN)),\n* nephrotic syndrome and\u002For renal dysfunction (scrum creatinine \\>2.0 mg\u002FdL or 160mmol\u002Fl, creatinine clearance \\\u003C15 ml\u002Fmin) at screening.\n* uncontrolled diabetes mellitus (Glycated hemoglobin \\>8.5%)","7 Years","80 Years",{"count":53,"type":20},1000,"10 Years","True prevalence of FH in the Russian Federation is unknown which leads to low percentage of diagnosed and treated cases. Research is needed to determine the prevalence of FH, specific diagnostic algorithms and optimal treatment strategies. The main aim of the present study is to evaluate the extent to which FH is underdiagnosed and undertreated in the Russian Federation for reduction of cardiovascular risk related to atherosclerosis in the country.\n\nAs a first step, total cholesterol (TC) and low-density lipoprotein (LDL-C) levels will be determined in a random sample from Moscow population (n=18000). It is expected that TC ≥ 7.5 mmol\u002FL will be detected in 10% of cohort. During 2014, approximately 500 patients will pass through non-invasive clinical examination at the Russian Cardiology Research and Production Center, including patient demographics, past medical history, family history of hypercholesterolemia, physical findings, current lipid-lowering therapies, blood tests, genetic analysis, echocardiography, carotid duplex ultrasound and exercise SPECT imaging in selected cases. On the basis of the Moscow Program four major Federal Medical Centers will be involved, and FH Registry will be created as a national, multi-center initiative to screen FH patients, control their diagnosis and management, and track clinical-reported outcomes over time.\n\nEstablishment of National Guidelines for the diagnosis and treatment of FH on the basis of these data and implementation those into clinical practice in different regions of Russia will allow improving patient care. As an expected outcome, this program will raise awareness and increase appropriate assessment and treatment of FH patients in Russia, leading to a timely detection of the disease and therapy initiation.",[57],"Familial Hypercholesterolemia",[59,60,61,62,63,64,65],"familial hypercholesterolemia","cholesterol","prevention","registry","atherosclerosis","treatment","prevalence","2022-11-01",{"date":68,"type":33},"2022-11-02",{"date":70,"type":4},"2014-01",{"date":72,"type":20},"2026-12-31",{"name":39,"class":40},5,""]